Abstract:The NLRP3 inflammasome is a critical component of innate immunity, which defends internal and external threats. However, inappropriate activation of the NLRP3 inflammasome induces various human diseases. In this study, we discovered and synthesized a series of tetrahydroquinoline inhibitors of NLRP3 inflammasome. Among these analogues, compound 6 exhibited optimal NLRP3 inhibitory activity. In vitro studies indicated that compound 6 directly bound to the NACHT domain of NLRP3 but not to protein pyrin domain (PYD) or LRR domain, inhibited NLRP3 ATPase activity, and blocked ASC oligomerization, thereby inhibiting NLRP3 inflammasome assembly and activation. Compound 6 specifically inhibited the NLRP3 inflammasome activation, but had no effect on the activation of NLRC4 or AIM2 inflammasomes. Furthermore, in the dextran sulfate sodium (DSS)-induced colitis mouse model, compound 6 exhibited significant anti-inflammatory activity through inhibiting NLRP3 inflammasome in vivo. Therefore, our study provides a potent NLRP3 inflammasome inhibitor, which deserves further structural optimization as a novel therapeutic candidate for NLRP3-driven diseases.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01924?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01924</a>.1H NMR, 13C NMR, and HPLC spectra analysis of all synthetic compounds; amino acid sequences of NLRP3 PYD domain, NACHT domain, and LRR domain; pharmacophore generation; pharmacophore and docking screening; small molecules in training set and testing set; and the activity tests of selected ligands (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01924/suppl_file/jm0c01924_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01924/suppl_file/jm0c01924_si_002.csv">CSV</a>)Recommended compound characterization checklist (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01924/suppl_file/jm0c01924_si_003.pdf">PDF</a>)Recommended compound characterization checklist (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01924/suppl_file/jm0c01924_si_004.xls">XLS</a>)This article has not yet been cited by other publications.

Design, synthesis and biological evaluation of sulfonylurea derivatives as NLRP3 inflammasome inhibitors

Novel Sulfonylurea-Based NLRP3 Inflammasome Inhibitor for Efficient Treatment of Nonalcoholic Steatohepatitis, Endotoxic Shock, and Colitis.

Design, synthesis and biological evaluation of novel diphenylamine analogues as NLRP3 inflammasome inhibitors

Design, Synthesis, and Pharmacological Characterization of Sulfonylurea-Based NLRP3 Inhibitors: Towards an Effective Therapeutic Strategy for Alzheimer's Disease

Structural insights of benzene sulfonamide analogs as NLRP3 inflammasome inhibitors: Design, synthesis, and biological characterization.

Discovery of N-phenyl-1-(phenylsulfonamido)cyclopropane-1-carboxamide Analogs As NLRP3 Inflammasome Inhibitors

Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome

Novel Isoalantolactone-Based Derivatives as Potent NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization

Synthesis and pharmacological validation of fluorescent diarylsulfonylurea analogues as NLRP3 inhibitors and imaging probes

Structure-based design and synthesis of sulfonylureas as novel NLRP3 inhibitors for Alzheimer’s disease

Functional Characterization of an Arylsulfonamide-Based Small-Molecule Inhibitor of the NLRP3 Inflammasome

Discovery of novel biphenyl-sulfonamide analogues as NLRP3 inflammasome inhibitors

Discovery, Total Synthesis, and Anti‐inflammatory Evaluation of Naturally Occurring Naphthopyrone‐Macrolide Hybrids as Potent NLRP3 Inflammasome Inhibitors

Discovery of 4-((E)-3,5-dimethoxy-2-((E)-2-nitrovinyl)styryl)aniline derivatives as potent and orally active NLRP3 inflammasome inhibitors for colitis

Pharmacological Inhibition of the Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome with MCC950

Discovery and Optimization of 4-Oxo-2-thioxo-thiazolidinones As NOD-like Receptor (NLR) Family, Pyrin Domain-Containing Protein 3 (NLRP3) Inhibitors.

Development of sulfonamide-based NLRP3 inhibitors: Further modifications and optimization through structure-activity relationship studies

Saponins as potential novel NLRP3 inflammasome inhibitors for inflammatory disorders

Development of Novel Tetrahydroquinoline Inhibitors of NLRP3 Inflammasome for Potential Treatment of DSS-Induced Mouse Colitis

New Highly Potent NLRP3 Inhibitors: Furanochalcone Velutone F Analogues.

Development and Characterization of a Hydroxyl-Sulfonamide Analogue, 5-Chloro-n-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, As a Novel NLRP3 Inflammasome Inhibitor for Potential Treatment of Multiple Sclerosis